img

Global RNA Vaccines Industry Research Report, Growth Trends and Competitive Analysis 2024-2034

Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare

Publisher : MRA | Format : PDF

Global RNA Vaccines Industry Research Report, Growth Trends and Competitive Analysis 2024-2034

RNA is a rather versatile technology and offers a number of advantages. RNA lacks genomic integration and its use results in transient expression of the encoded protein. This favorable safety profile makes RNA especially attractive for vaccines and gene editing. RNA is well defined chemically which ensures reproducible manufacturing at high yield, purity and activity. Improvements of lipid nanoparticle formulations as a vehicle for in vivo systemic delivery of RNA has greatly favored the development of in vivo transfection strategies.
RNA Vaccines & Therapeutics is in the development stage and there is no use in the market. The fastest research is Clinical phrase II, such as AGS-004 of Argos Therapeutics, SB-FIX, SB-318, SB-913 of Sangamo Therapeutics. The major application of RNA Vaccines & Therapeutics is for infectious disease, cancer and others. And infectious disease and cancer are the major applications.
The global RNA Vaccines market size was US$ million in 2022 and is forecast to a readjusted size of US$ million by 2034 with a CAGR of % during the forecast period 2024-2034.
The United States market for RNA Vaccines is estimated to increase from $ million in 2024 to reach $ million by 2034, at a CAGR of % during the forecast period of 2024 through 2034.
The China market for RNA Vaccines is estimated to increase from $ million in 2024 to reach $ million by 2034, at a CAGR of % during the forecast period of 2024 through 2034.
The Europe market for RNA Vaccines is estimated to increase from $ million in 2024 to reach $ million by 2034, at a CAGR of % during the forecast period of 2024 through 2034..
The global key manufacturers of RNA Vaccines include Moderna Therapeutics, CureVac, Translate Bio, BioNTech, Sangamo Therapeutics, Argos Therapeutics, In-Cell-Art, eTheRNA and Ethris, etc. In 2022, the global top five players hold a share approximately % in sales volume, and in term of revenue of RNA Vaccines, the top five companies hold a share nearly %.
In terms of sales (consumption) side, this report focuses on the sales of RNA Vaccines by regions (Countries), company, by type and by type. from 2018 to 2024 and forecast to 2034.
The global RNA Vaccines market is thoroughly, accurately, and comprehensively assessed in the report with a large focus on market dynamics, market competition, regional growth, segmental analysis, and key growth strategies. Buyers of the report will have access to verified market figures, including global market size in terms of revenue and volume. As part of sales analysis, the authors of the report have provided reliable estimations and calculations for global revenue and sales by type segment of the global RNA Vaccines market. These figures have been provided in terms of both revenue and sales for the period 2018-2034. Additionally, the report provides accurate figures for sales by region in terms of revenue as well as volume for the same period.



By Company


Moderna Therapeutics
CureVac
Translate Bio
BioNTech
Sangamo Therapeutics
Argos Therapeutics
In-Cell-Art
eTheRNA
Ethris
Tiba Biotechnology
By Type
Individualized Cancer Treatment MRNA Vaccine
Infectious Disease Treatment MRNA Vaccine
Infection Prevention MRNA Vaccine
By Application
Infectious Disease
Cancer
Other
Sales by Region
North America
U.S.
Canada
China
APAC (excluding China)
Japan
South Korea
China Taiwan
Southeast Asia
Europe
Germany
France
U.K.
Italy
Russia
Middle East, Africa, Latin America
Brazil
Mexico
Turkey
Israel
GCC Countries

Chapter Outline


Chapter 1Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2Sales (consumption), revenue of RNA Vaccines in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 3Detailed analysis of RNA Vaccines manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6North America by company, by type, by application and by country, sales, and revenue for each segment.
Chapter 7Europe by company, by type, by application and by country, sales, and revenue for each segment.
Chapter 8China by company, by type and by application, sales, and revenue for each segment.
Chapter 9APAC (excluding China) by company, by type, by application and by region, sales, and revenue for each segment.
Chapter 10Middle East, Africa, and Latin America by company, by type, by application and by country, sales, and revenue for each segment.
Chapter 11Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, RNA Vaccines sales, revenue, price, gross margin, and recent development, etc.
Chapter 12Analysis of industrial chain, sales channel, key raw materials, distributors, and customers.
Chapter 13Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 14The main points and conclusions of the report.

Table of Content

1 Report Overview
1.1 RNA Vaccines Definition
1.2 Market by Type
1.2.1 Global RNA Vaccines Market Size Growth Rate by Type, 2018 VS 2022 VS 2034
1.2.2 Individualized Cancer Treatment MRNA Vaccine
1.2.3 Infectious Disease Treatment MRNA Vaccine
1.2.4 Infection Prevention MRNA Vaccine
1.3 Market Segment by Application
1.3.1 Global RNA Vaccines Market Size Growth Rate by Application, 2018 VS 2022 VS 2034
1.3.2 Infectious Disease
1.3.3 Cancer
1.3.4 Other
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global RNA Vaccines Sales
2.1 Global RNA Vaccines Revenue Estimates and Forecasts 2018-2034
2.2 Global RNA Vaccines Revenue by Region: 2018 VS 2022 VS 2034
2.3 Global RNA Vaccines Revenue by Region
2.3.1 Global RNA Vaccines Revenue by Region (2018-2024)
2.3.2 Global RNA Vaccines Revenue by Region (2024-2034)
2.4 Global RNA Vaccines Sales Quantity Estimates and Forecasts 2018-2034
2.5 Global RNA Vaccines Sales Quantity by Region: 2018 VS 2022 VS 2034
2.6 Global RNA Vaccines Sales Quantity by Region
2.6.1 Global RNA Vaccines Sales Quantity by Region (2018-2024)
2.6.2 Global RNA Vaccines Sales Quantity by Region (2024-2034)
2.7 North America
2.8 Europe
2.9 China
2.10 APAC (excluding China)
2.11 Middle East, Africa and Latin America
3 Competition by Manufacturers
3.1 Global RNA Vaccines Sales Quantity by Manufacturers
3.1.1 Global RNA Vaccines Sales Quantity by Manufacturers (2018-2024)
3.1.2 Global RNA Vaccines Sales Quantity Share by Manufacturers (2018-2024)
3.1.3 Global Top 10 and Top 5 Companies by RNA Vaccines Sales in 2022
3.2 Global RNA Vaccines Revenue by Manufacturers
3.2.1 Global RNA Vaccines Revenue by Manufacturers (2018-2024)
3.2.2 Global RNA Vaccines Revenue Share by Manufacturers (2018-2024)
3.2.3 Global Top 10 and Top 5 Companies by RNA Vaccines Revenue in 2022
3.3 Global RNA Vaccines Sales Price by Manufacturers
3.4 Global Key Players of RNA Vaccines, Industry Ranking, 2021 VS 2022
3.5 Analysis of Competitive Landscape
3.5.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
3.5.2 Global RNA Vaccines Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.6 Global Key Manufacturers of RNA Vaccines, Manufacturing Base Distribution and Headquarters
3.7 Global Key Manufacturers of RNA Vaccines, Product Offered and Application
3.8 Global Key Manufacturers of RNA Vaccines, Date of Enter into This Industry
3.9 Mergers & Acquisitions, Expansion Plans
4 Estimates and Forecasts by Type
4.1 Global RNA Vaccines Sales Quantity by Type
4.1.1 Global RNA Vaccines Historical Sales Quantity by Type (2018-2024)
4.1.2 Global RNA Vaccines Forecasted Sales Quantity by Type (2024-2034)
4.1.3 Global RNA Vaccines Sales Quantity Market Share by Type (2018-2034)
4.2 Global RNA Vaccines Revenue by Type
4.2.1 Global RNA Vaccines Historical Revenue by Type (2018-2024)
4.2.2 Global RNA Vaccines Forecasted Revenue by Type (2024-2034)
4.2.3 Global RNA Vaccines Revenue Market Share by Type (2018-2034)
4.3 Global RNA Vaccines Price by Type
4.3.1 Global RNA Vaccines Price by Type (2018-2024)
4.3.2 Global RNA Vaccines Price Forecast by Type (2024-2034)
5 Market Size by Application
5.1 Global RNA Vaccines Sales Quantity by Application
5.1.1 Global RNA Vaccines Historical Sales Quantity by Application (2018-2024)
5.1.2 Global RNA Vaccines Forecasted Sales Quantity by Application (2024-2034)
5.1.3 Global RNA Vaccines Sales Quantity Market Share by Application (2018-2034)
5.2 Global RNA Vaccines Revenue by Application
5.2.1 Global RNA Vaccines Historical Revenue by Application (2018-2024)
5.2.2 Global RNA Vaccines Forecasted Revenue by Application (2024-2034)
5.2.3 Global RNA Vaccines Revenue Market Share by Application (2018-2034)
5.3 Global RNA Vaccines Price by Application
5.3.1 Global RNA Vaccines Price by Application (2018-2024)
5.3.2 Global RNA Vaccines Price Forecast by Application (2024-2034)
6 North America
6.1 North America RNA Vaccines Sales by Company
6.1.1 North America RNA Vaccines Revenue by Company (2018-2024)
6.1.2 North America RNA Vaccines Sales Quantity by Company (2018-2024)
6.2 North America RNA Vaccines Market Size by Type
6.2.1 North America RNA Vaccines Sales Quantity by Type (2018-2034)
6.2.2 North America RNA Vaccines Revenue by Type (2018-2034)
6.3 North America RNA Vaccines Market Size by Application
6.3.1 North America RNA Vaccines Sales Quantity by Application (2018-2034)
6.3.2 North America RNA Vaccines Revenue by Application (2018-2034)
6.4 North America RNA Vaccines Market Size by Country
6.4.1 North America RNA Vaccines Revenue by Country: 2018 VS 2022 VS 2034
6.4.2 North America RNA Vaccines Revenue by Country (2018-2034)
6.4.3 North America RNA Vaccines Sales Quantity by Country (2018-2034)
6.4.4 U.S.
6.4.5 Canada
7 Europe
7.1 Europe RNA Vaccines Sales by Company
7.1.1 Europe RNA Vaccines Sales Quantity by Company (2018-2024)
7.1.2 Europe RNA Vaccines Revenue by Company (2018-2024)
7.2 Europe RNA Vaccines Market Size by Type
7.2.1 Europe RNA Vaccines Sales Quantity by Type (2018-2034)
7.2.2 Europe RNA Vaccines Revenue by Type (2018-2034)
7.3 Europe RNA Vaccines Market Size by Application
7.3.1 Europe RNA Vaccines Sales Quantity by Application (2018-2034)
7.3.2 Europe RNA Vaccines Revenue by Application (2018-2034)
7.4 Europe RNA Vaccines Market Size by Country
7.4.1 Europe RNA Vaccines Revenue by Country: 2018 VS 2022 VS 2034
7.4.2 Europe RNA Vaccines Revenue by Country (2018-2034)
7.4.3 Europe RNA Vaccines Sales Quantity by Country (2018-2034)
7.4.4 Germany
7.4.5 France
7.4.6 U.K.
7.4.7 Italy
7.4.8 Russia
8 China
8.1 China RNA Vaccines Sales by Company
8.1.1 China RNA Vaccines Sales Quantity by Company (2018-2024)
8.1.2 China RNA Vaccines Revenue by Company (2018-2024)
8.2 China RNA Vaccines Market Size by Type
8.2.1 China RNA Vaccines Sales Quantity by Type (2018-2034)
8.2.2 China RNA Vaccines Revenue by Type (2018-2034)
8.3 China RNA Vaccines Market Size by Application
8.3.1 China RNA Vaccines Sales Quantity by Application (2018-2034)
8.3.2 China RNA Vaccines Revenue by Application (2018-2034)
9 APAC (excluding China)
9.1 APAC RNA Vaccines Sales by Company
9.1.1 APAC RNA Vaccines Sales Quantity by Company (2018-2024)
9.1.2 APAC RNA Vaccines Revenue by Company (2018-2024)
9.2 APAC RNA Vaccines Market Size by Type
9.2.1 APAC RNA Vaccines Sales Quantity by Type (2018-2034)
9.2.2 APAC RNA Vaccines Revenue by Type (2018-2034)
9.3 APAC RNA Vaccines Market Size by Application
9.3.1 APAC RNA Vaccines Sales Quantity by Application (2018-2034)
9.3.2 APAC RNA Vaccines Revenue by Application (2018-2034)
9.4 APAC RNA Vaccines Market Size by Region
9.4.1 APAC RNA Vaccines Revenue by Region: 2018 VS 2022 VS 2034
9.4.2 APAC RNA Vaccines Revenue by Region (2018-2034)
9.4.3 APAC RNA Vaccines Sales Quantity by Region (2018-2034)
9.4.4 Japan
9.4.5 South Korea
9.4.6 China Taiwan
9.4.7 Southeast Asia
9.4.8 India
10 Middle East, Africa and Latin America
10.1 Middle East, Africa and Latin America RNA Vaccines Sales by Company
10.1.1 Middle East, Africa and Latin America RNA Vaccines Sales Quantity by Company (2018-2024)
10.1.2 Middle East, Africa and Latin America RNA Vaccines Revenue by Company (2018-2024)
10.2 Middle East, Africa and Latin America RNA Vaccines Market Size by Type
10.2.1 Middle East, Africa and Latin America RNA Vaccines Sales Quantity by Type (2018-2034)
10.2.2 Middle East, Africa and Latin America RNA Vaccines Revenue by Type (2018-2034)
10.3 Middle East, Africa and Latin America RNA Vaccines Market Size by Application
10.3.1 Middle East, Africa and Latin America RNA Vaccines Sales Quantity by Application (2018-2034)
10.3.2 Middle East, Africa and Latin America RNA Vaccines Revenue by Application (2018-2034)
10.4 Middle East, Africa and Latin America RNA Vaccines Market Size by Country
10.4.1 Middle East, Africa and Latin America RNA Vaccines Revenue by Country: 2018 VS 2022 VS 2034
10.4.2 Middle East, Africa and Latin America RNA Vaccines Revenue by Country (2018-2034)
10.4.3 Middle East, Africa and Latin America RNA Vaccines Sales Quantity by Country (2018-2034)
10.4.4 Brazil
10.4.5 Mexico
10.4.6 Turkey
10.4.7 Israel
10.4.8 GCC Countries
11 Company Profiles
11.1 Moderna Therapeutics
11.1.1 Moderna Therapeutics Company Information
11.1.2 Moderna Therapeutics Overview
11.1.3 Moderna Therapeutics RNA Vaccines Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.1.4 Moderna Therapeutics RNA Vaccines Products and Services
11.1.5 Moderna Therapeutics RNA Vaccines SWOT Analysis
11.1.6 Moderna Therapeutics Recent Developments
11.2 CureVac
11.2.1 CureVac Company Information
11.2.2 CureVac Overview
11.2.3 CureVac RNA Vaccines Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.2.4 CureVac RNA Vaccines Products and Services
11.2.5 CureVac RNA Vaccines SWOT Analysis
11.2.6 CureVac Recent Developments
11.3 Translate Bio
11.3.1 Translate Bio Company Information
11.3.2 Translate Bio Overview
11.3.3 Translate Bio RNA Vaccines Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.3.4 Translate Bio RNA Vaccines Products and Services
11.3.5 Translate Bio RNA Vaccines SWOT Analysis
11.3.6 Translate Bio Recent Developments
11.4 BioNTech
11.4.1 BioNTech Company Information
11.4.2 BioNTech Overview
11.4.3 BioNTech RNA Vaccines Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.4.4 BioNTech RNA Vaccines Products and Services
11.4.5 BioNTech RNA Vaccines SWOT Analysis
11.4.6 BioNTech Recent Developments
11.5 Sangamo Therapeutics
11.5.1 Sangamo Therapeutics Company Information
11.5.2 Sangamo Therapeutics Overview
11.5.3 Sangamo Therapeutics RNA Vaccines Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.5.4 Sangamo Therapeutics RNA Vaccines Products and Services
11.5.5 Sangamo Therapeutics RNA Vaccines SWOT Analysis
11.5.6 Sangamo Therapeutics Recent Developments
11.6 Argos Therapeutics
11.6.1 Argos Therapeutics Company Information
11.6.2 Argos Therapeutics Overview
11.6.3 Argos Therapeutics RNA Vaccines Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.6.4 Argos Therapeutics RNA Vaccines Products and Services
11.6.5 Argos Therapeutics RNA Vaccines SWOT Analysis
11.6.6 Argos Therapeutics Recent Developments
11.7 In-Cell-Art
11.7.1 In-Cell-Art Company Information
11.7.2 In-Cell-Art Overview
11.7.3 In-Cell-Art RNA Vaccines Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.7.4 In-Cell-Art RNA Vaccines Products and Services
11.7.5 In-Cell-Art RNA Vaccines SWOT Analysis
11.7.6 In-Cell-Art Recent Developments
11.8 eTheRNA
11.8.1 eTheRNA Company Information
11.8.2 eTheRNA Overview
11.8.3 eTheRNA RNA Vaccines Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.8.4 eTheRNA RNA Vaccines Products and Services
11.8.5 eTheRNA RNA Vaccines SWOT Analysis
11.8.6 eTheRNA Recent Developments
11.9 Ethris
11.9.1 Ethris Company Information
11.9.2 Ethris Overview
11.9.3 Ethris RNA Vaccines Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.9.4 Ethris RNA Vaccines Products and Services
11.9.5 Ethris RNA Vaccines SWOT Analysis
11.9.6 Ethris Recent Developments
11.10 Tiba Biotechnology
11.10.1 Tiba Biotechnology Company Information
11.10.2 Tiba Biotechnology Overview
11.10.3 Tiba Biotechnology RNA Vaccines Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.10.4 Tiba Biotechnology RNA Vaccines Products and Services
11.10.5 Tiba Biotechnology RNA Vaccines SWOT Analysis
11.10.6 Tiba Biotechnology Recent Developments
12 Value Chain and Sales Channels Analysis
12.1 RNA Vaccines Value Chain Analysis
12.2 RNA Vaccines Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 RNA Vaccines Production Mode & Process
12.4 RNA Vaccines Sales and Marketing
12.4.1 RNA Vaccines Sales Channels
12.4.2 RNA Vaccines Distributors
12.5 RNA Vaccines Customers
13 Market Dynamics
13.1 RNA Vaccines Industry Trends
13.2 RNA Vaccines Market Drivers
13.3 RNA Vaccines Market Challenges
13.4 RNA Vaccines Market Restraints
14 Key Findings
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer

List of Figure

List of Tables
Table 1. Global RNA Vaccines Market Size Growth Rate (CAGR) by Type, 2018 VS 2022 VS 2034 (US$ Million)
Table 2. Major Manufacturers of Individualized Cancer Treatment MRNA Vaccine
Table 3. Major Manufacturers of Infectious Disease Treatment MRNA Vaccine
Table 4. Major Manufacturers of Infection Prevention MRNA Vaccine
Table 5. Global RNA Vaccines Market Size Growth Rate (CAGR) by Application, 2018 VS 2022 VS 2034 (US$ Million)
Table 6. Global RNA Vaccines Revenue by Region: 2018 VS 2022 VS 2034 (US$ Million)
Table 7. Global RNA Vaccines Revenue by Region (2018-2024) & (US$ Million)
Table 8. Global RNA Vaccines Revenue Market Share by Region (2018-2024)
Table 9. Global RNA Vaccines Revenue by Region (2024-2034) & (US$ Million)
Table 10. Global RNA Vaccines Revenue Market Share by Region (2024-2034)
Table 11. Global RNA Vaccines Sales Quantity by Region: 2018 VS 2022 VS 2034 (K Doses)
Table 12. Global RNA Vaccines Sales by Region (2018-2024) & (K Doses)
Table 13. Global RNA Vaccines Sales Market Share by Region (2018-2024)
Table 14. Global RNA Vaccines Sales by Region (2024-2034) & (K Doses)
Table 15. Global RNA Vaccines Sales Market Share by Region (2024-2034)
Table 16. Global RNA Vaccines Sales Quantity by Manufacturers (2018-2024) & (K Doses)
Table 17. Global RNA Vaccines Sales Quantity Share by Manufacturers (2018-2024)
Table 18. Global RNA Vaccines Revenue by Manufacturers (2018-2024) & (US$ Million)
Table 19. Global RNA Vaccines Revenue Share by Manufacturers (2018-2024)
Table 20. Global RNA Vaccines Price by Manufacturers 2018-2024 (USD/Dose)
Table 21. Global Key Players of RNA Vaccines, Industry Ranking, 2021 VS 2022
Table 22. Global RNA Vaccines Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 23. Global RNA Vaccines by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in RNA Vaccines as of 2022)
Table 24. Global Key Manufacturers of RNA Vaccines, Manufacturing Base Distribution and Headquarters
Table 25. Global Key Manufacturers of RNA Vaccines, Product Offered and Application
Table 26. Global Key Manufacturers of RNA Vaccines, Date of Enter into This Industry
Table 27. Mergers & Acquisitions, Expansion Plans
Table 28. Global RNA Vaccines Sales Quantity by Type (2018-2024) & (K Doses)
Table 29. Global RNA Vaccines Sales Quantity by Type (2024-2034) & (K Doses)
Table 30. Global RNA Vaccines Sales Quantity Share by Type (2018-2024)
Table 31. Global RNA Vaccines Sales Quantity Share by Type (2024-2034)
Table 32. Global RNA Vaccines Revenue by Type (2018-2024) & (US$ Million)
Table 33. Global RNA Vaccines Revenue by Type (2024-2034) & (US$ Million)
Table 34. Global RNA Vaccines Revenue Share by Type (2018-2024)
Table 35. Global RNA Vaccines Revenue Share by Type (2024-2034)
Table 36. RNA Vaccines Price by Type (2018-2024) & (USD/Dose)
Table 37. Global RNA Vaccines Price Forecast by Type (2024-2034) & (USD/Dose)
Table 38. Global RNA Vaccines Sales Quantity by Application (2018-2024) & (K Doses)
Table 39. Global RNA Vaccines Sales Quantity by Application (2024-2034) & (K Doses)
Table 40. Global RNA Vaccines Sales Quantity Share by Application (2018-2024)
Table 41. Global RNA Vaccines Sales Quantity Share by Application (2024-2034)
Table 42. Global RNA Vaccines Revenue by Application (2018-2024) & (US$ Million)
Table 43. Global RNA Vaccines Revenue by Application (2024-2034) & (US$ Million)
Table 44. Global RNA Vaccines Revenue Share by Application (2018-2024)
Table 45. Global RNA Vaccines Revenue Share by Application (2024-2034)
Table 46. RNA Vaccines Price by Application (2018-2024) & (USD/Dose)
Table 47. Global RNA Vaccines Price Forecast by Application (2024-2034) & (USD/Dose)
Table 48. North America RNA Vaccines Revenue by Company (2018-2024) & (US$ Million)
Table 49. North America RNA Vaccines Sales Quantity by Company (2018-2024) & (K Doses)
Table 50. North America RNA Vaccines Sales Quantity by Type (2018-2024) & (K Doses)
Table 51. North America RNA Vaccines Sales Quantity by Type (2024-2034) & (K Doses)
Table 52. North America RNA Vaccines Revenue by Type (2018-2024) & (US$ Million)
Table 53. North America RNA Vaccines Revenue by Type (2024-2034) & (US$ Million)
Table 54. North America RNA Vaccines Sales Quantity by Application (2018-2024) & (K Doses)
Table 55. North America RNA Vaccines Sales Quantity by Application (2024-2034) & (K Doses)
Table 56. North America RNA Vaccines Revenue by Application (2018-2024) & (US$ Million)
Table 57. North America RNA Vaccines Revenue by Application (2024-2034) & (US$ Million)
Table 58. North America RNA Vaccines Revenue by Country: 2018 VS 2022 VS 2034 (US$ Million)
Table 59. North America RNA Vaccines Revenue by Country (2018-2024) & (US$ Million)
Table 60. North America RNA Vaccines Revenue by Country (2024-2034) & (US$ Million)
Table 61. North America RNA Vaccines Sales Quantity by Country (2018-2024) & (K Doses)
Table 62. North America RNA Vaccines Sales Quantity by Country (2024-2034) & (K Doses)
Table 63. Europe RNA Vaccines Sales Quantity by Company (2018-2024) & (K Doses)
Table 64. Europe RNA Vaccines Revenue by Company (2018-2024) & (US$ Million)
Table 65. Europe RNA Vaccines Sales Quantity by Type (2018-2024) & (K Doses)
Table 66. Europe RNA Vaccines Sales Quantity by Type (2024-2034) & (K Doses)
Table 67. Europe RNA Vaccines Revenue by Type (2018-2024) & (US$ Million)
Table 68. Europe RNA Vaccines Revenue by Type (2024-2034) & (US$ Million)
Table 69. Europe RNA Vaccines Sales Quantity by Application (2018-2024) & (K Doses)
Table 70. Europe RNA Vaccines Sales Quantity by Application (2024-2034) & (K Doses)
Table 71. Europe RNA Vaccines Revenue by Application (2018-2024) & (US$ Million)
Table 72. Europe RNA Vaccines Revenue by Application (2024-2034) & (US$ Million)
Table 73. Europe RNA Vaccines Revenue by Country: 2018 VS 2022 VS 2034 (US$ Million)
Table 74. Europe RNA Vaccines Revenue by Country (2018-2024) & (US$ Million)
Table 75. Europe RNA Vaccines Revenue by Country (2024-2034) & (US$ Million)
Table 76. Europe RNA Vaccines Sales Quantity by Country (2018-2024) & (K Doses)
Table 77. Europe RNA Vaccines Sales Quantity by Country (2024-2034) & (K Doses)
Table 78. China RNA Vaccines Sales Quantity by Company (2018-2024) & (K Doses)
Table 79. China RNA Vaccines Revenue by Company (2018-2024) & (US$ Million)
Table 80. China RNA Vaccines Sales Quantity by Type (2018-2024) & (K Doses)
Table 81. China RNA Vaccines Sales Quantity by Type (2024-2034) & (K Doses)
Table 82. China RNA Vaccines Revenue by Type (2018-2024) & (US$ Million)
Table 83. China RNA Vaccines Revenue by Type (2024-2034) & (US$ Million)
Table 84. China RNA Vaccines Sales Quantity by Application (2018-2024) & (K Doses)
Table 85. China RNA Vaccines Sales Quantity by Application (2024-2034) & (K Doses)
Table 86. China RNA Vaccines Revenue by Application (2018-2024) & (US$ Million)
Table 87. China RNA Vaccines Revenue by Application (2024-2034) & (US$ Million)
Table 88. APAC RNA Vaccines Sales Quantity by Company (2018-2024) & (K Doses)
Table 89. APAC RNA Vaccines Revenue by Company (2018-2024) & (US$ Million)
Table 90. APAC RNA Vaccines Sales Quantity by Type (2018-2024) & (K Doses)
Table 91. APAC RNA Vaccines Sales Quantity by Type (2024-2034) & (K Doses)
Table 92. APAC RNA Vaccines Revenue by Type (2018-2024) & (US$ Million)
Table 93. APAC RNA Vaccines Revenue by Type (2024-2034) & (US$ Million)
Table 94. APAC RNA Vaccines Sales Quantity by Application (2018-2024) & (K Doses)
Table 95. APAC RNA Vaccines Sales Quantity by Application (2024-2034) & (K Doses)
Table 96. APAC RNA Vaccines Revenue by Application (2018-2024) & (US$ Million)
Table 97. APAC RNA Vaccines Revenue by Application (2024-2034) & (US$ Million)
Table 98. APAC RNA Vaccines Revenue by Region: 2018 VS 2022 VS 2034 (US$ Million)
Table 99. APAC RNA Vaccines Revenue by Region (2018-2024) & (US$ Million)
Table 100. APAC RNA Vaccines Revenue by Region (2024-2034) & (US$ Million)
Table 101. APAC RNA Vaccines Sales Quantity by Region (2018-2024) & (K Doses)
Table 102. APAC RNA Vaccines Sales Quantity by Region (2024-2034) & (K Doses)
Table 103. Middle East, Africa and Latin America RNA Vaccines Sales Quantity by Company (2018-2024) & (K Doses)
Table 104. Middle East, Africa and Latin America RNA Vaccines Revenue by Company (2018-2024) & (US$ Million)
Table 105. Middle East, Africa and Latin America RNA Vaccines Sales Quantity by Type (2018-2024) & (K Doses)
Table 106. Middle East, Africa and Latin America RNA Vaccines Sales Quantity by Type (2024-2034) & (K Doses)
Table 107. Middle East, Africa and Latin America RNA Vaccines Revenue by Type (2018-2024) & (US$ Million)
Table 108. Middle East, Africa and Latin America RNA Vaccines Revenue by Type (2024-2034) & (US$ Million)
Table 109. Middle East, Africa and Latin America RNA Vaccines Sales Quantity by Application (2018-2024) & (K Doses)
Table 110. Middle East, Africa and Latin America RNA Vaccines Sales Quantity by Application (2024-2034) & (K Doses)
Table 111. Middle East, Africa and Latin America RNA Vaccines Revenue by Application (2018-2024) & (US$ Million)
Table 112. Middle East, Africa and Latin America RNA Vaccines Revenue by Application (2024-2034) & (US$ Million)
Table 113. Middle East, Africa and Latin America RNA Vaccines Revenue by Country: 2018 VS 2022 VS 2034 (US$ Million)
Table 114. Middle East, Africa and Latin America RNA Vaccines Revenue by Country (2018-2024) & (US$ Million)
Table 115. Middle East, Africa and Latin America RNA Vaccines Revenue by Country (2024-2034) & (US$ Million)
Table 116. Middle East, Africa and Latin America RNA Vaccines Sales Quantity by Country (2018-2024) & (K Doses)
Table 117. Middle East, Africa and Latin America RNA Vaccines Sales Quantity by Country (2024-2034) & (K Doses)
Table 118. Moderna Therapeutics Company Information
Table 119. Moderna Therapeutics Description and Overview
Table 120. Moderna Therapeutics RNA Vaccines Sales Quantity (K Doses), Revenue (US$ Million), Average Selling Price (ASP) (USD/Dose) and Gross Margin (2018-2024)
Table 121. Moderna Therapeutics RNA Vaccines Product and Services
Table 122. Moderna Therapeutics RNA Vaccines SWOT Analysis
Table 123. Moderna Therapeutics Recent Developments
Table 124. CureVac Company Information
Table 125. CureVac Description and Overview
Table 126. CureVac RNA Vaccines Sales Quantity (K Doses), Revenue (US$ Million), Average Selling Price (ASP) (USD/Dose) and Gross Margin (2018-2024)
Table 127. CureVac RNA Vaccines Product and Services
Table 128. CureVac RNA Vaccines SWOT Analysis
Table 129. CureVac Recent Developments
Table 130. Translate Bio Company Information
Table 131. Translate Bio Description and Overview
Table 132. Translate Bio RNA Vaccines Sales Quantity (K Doses), Revenue (US$ Million), Average Selling Price (ASP) (USD/Dose) and Gross Margin (2018-2024)
Table 133. Translate Bio RNA Vaccines Product and Services
Table 134. Translate Bio RNA Vaccines SWOT Analysis
Table 135. Translate Bio Recent Developments
Table 136. BioNTech Company Information
Table 137. BioNTech Description and Overview
Table 138. BioNTech RNA Vaccines Sales Quantity (K Doses), Revenue (US$ Million), Average Selling Price (ASP) (USD/Dose) and Gross Margin (2018-2024)
Table 139. BioNTech RNA Vaccines Product and Services
Table 140. BioNTech RNA Vaccines SWOT Analysis
Table 141. BioNTech Recent Developments
Table 142. Sangamo Therapeutics Company Information
Table 143. Sangamo Therapeutics Description and Overview
Table 144. Sangamo Therapeutics RNA Vaccines Sales Quantity (K Doses), Revenue (US$ Million), Average Selling Price (ASP) (USD/Dose) and Gross Margin (2018-2024)
Table 145. Sangamo Therapeutics RNA Vaccines Product and Services
Table 146. Sangamo Therapeutics RNA Vaccines SWOT Analysis
Table 147. Sangamo Therapeutics Recent Developments
Table 148. Argos Therapeutics Company Information
Table 149. Argos Therapeutics Description and Overview
Table 150. Argos Therapeutics RNA Vaccines Sales Quantity (K Doses), Revenue (US$ Million), Average Selling Price (ASP) (USD/Dose) and Gross Margin (2018-2024)
Table 151. Argos Therapeutics RNA Vaccines Product and Services
Table 152. Argos Therapeutics RNA Vaccines SWOT Analysis
Table 153. Argos Therapeutics Recent Developments
Table 154. In-Cell-Art Company Information
Table 155. In-Cell-Art Description and Overview
Table 156. In-Cell-Art RNA Vaccines Sales Quantity (K Doses), Revenue (US$ Million), Average Selling Price (ASP) (USD/Dose) and Gross Margin (2018-2024)
Table 157. In-Cell-Art RNA Vaccines Product and Services
Table 158. In-Cell-Art RNA Vaccines SWOT Analysis
Table 159. In-Cell-Art Recent Developments
Table 160. eTheRNA Company Information
Table 161. eTheRNA Description and Overview
Table 162. eTheRNA RNA Vaccines Sales Quantity (K Doses), Revenue (US$ Million), Average Selling Price (ASP) (USD/Dose) and Gross Margin (2018-2024)
Table 163. eTheRNA RNA Vaccines Product and Services
Table 164. eTheRNA RNA Vaccines SWOT Analysis
Table 165. eTheRNA Recent Developments
Table 166. Ethris Company Information
Table 167. Ethris Description and Overview
Table 168. Ethris RNA Vaccines Sales Quantity (K Doses), Revenue (US$ Million), Average Selling Price (ASP) (USD/Dose) and Gross Margin (2018-2024)
Table 169. Ethris RNA Vaccines Product and Services
Table 170. Ethris RNA Vaccines SWOT Analysis
Table 171. Ethris Recent Developments
Table 172. Tiba Biotechnology Company Information
Table 173. Tiba Biotechnology Description and Overview
Table 174. Tiba Biotechnology RNA Vaccines Sales Quantity (K Doses), Revenue (US$ Million), Average Selling Price (ASP) (USD/Dose) and Gross Margin (2018-2024)
Table 175. Tiba Biotechnology RNA Vaccines Product and Services
Table 176. Tiba Biotechnology RNA Vaccines SWOT Analysis
Table 177. Tiba Biotechnology Recent Developments
Table 178. Key Raw Materials Lists
Table 179. Raw Materials Key Suppliers Lists
Table 180. RNA Vaccines Distributors List
Table 181. RNA Vaccines Customers List
Table 182. RNA Vaccines Market Trends
Table 183. RNA Vaccines Market Drivers
Table 184. RNA Vaccines Market Challenges
Table 185. RNA Vaccines Market Restraints
Table 186. Research Programs/Design for This Report
Table 187. Key Data Information from Secondary Sources
Table 188. Key Data Information from Primary Sources
List of Figures
Figure 1. RNA Vaccines Product Picture
Figure 2. Global RNA Vaccines Market Size Growth Rate by Type, 2018 VS 2022 VS 2034 (US$ Million)
Figure 3. Global RNA Vaccines Market Share by Type in 2022 & 2034
Figure 4. Individualized Cancer Treatment MRNA Vaccine Product Picture
Figure 5. Infectious Disease Treatment MRNA Vaccine Product Picture
Figure 6. Infection Prevention MRNA Vaccine Product Picture
Figure 7. Global RNA Vaccines Market Size Growth Rate by Application, 2018 VS 2022 VS 2034 (US$ Million)
Figure 8. Global RNA Vaccines Market Share by Application in 2022 & 2034
Figure 9. Infectious Disease
Figure 10. Cancer
Figure 11. Other
Figure 12. RNA Vaccines Report Years Considered
Figure 13. Global RNA Vaccines Revenue, (US$ Million), 2018 VS 2022 VS 2034
Figure 14. Global RNA Vaccines Revenue 2018-2034 (US$ Million)
Figure 15. Global RNA Vaccines Revenue Market Share by Region in Percentage: 2022 Versus 2034
Figure 16. Global RNA Vaccines Sales Quantity 2018-2034 (K Doses)
Figure 17. Global RNA Vaccines Sales Quantity Market Share by Region (2018-2024)
Figure 18. Global RNA Vaccines Sales Quantity Market Share by Region (2024-2034)
Figure 19. North America RNA Vaccines Sales Quantity YoY (2018-2034) & (K Doses)
Figure 20. North America RNA Vaccines Revenue YoY (2018-2034) & (US$ Million)
Figure 21. Europe RNA Vaccines Sales Quantity YoY (2018-2034) & (K Doses)
Figure 22. Europe RNA Vaccines Revenue YoY (2018-2034) & (US$ Million)
Figure 23. China RNA Vaccines Sales Quantity YoY (2018-2034) & (K Doses)
Figure 24. China RNA Vaccines Revenue YoY (2018-2034) & (US$ Million)
Figure 25. APAC RNA Vaccines Sales Quantity YoY (2018-2034) & (K Doses)
Figure 26. APAC RNA Vaccines Revenue YoY (2018-2034) & (US$ Million)
Figure 27. Middle East, Africa and Latin America RNA Vaccines Sales Quantity YoY (2018-2034) & (K Doses)
Figure 28. Middle East, Africa and Latin America RNA Vaccines Revenue YoY (2018-2034) & (US$ Million)
Figure 29. The Top 10 and Top 5 Players Market Share by RNA Vaccines Sales Quantity in 2022
Figure 30. The Top 10 and Top 5 Players Market Share by RNA Vaccines Revenue in 2022
Figure 31. RNA Vaccines Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2018 VS 2022
Figure 32. Global RNA Vaccines Sales Quantity Market Share by Type (2018-2034)
Figure 33. Global RNA Vaccines Revenue Market Share by Type (2018-2034)
Figure 34. Global RNA Vaccines Sales Quantity Market Share by Application (2018-2034)
Figure 35. Global RNA Vaccines Revenue Market Share by Application (2018-2034)
Figure 36. North America RNA Vaccines Revenue Market Share by Company in 2022
Figure 37. North America RNA Vaccines Sales Quantity Market Share by Company in 2022
Figure 38. North America RNA Vaccines Sales Quantity Market Share by Type (2018-2034)
Figure 39. North America RNA Vaccines Revenue Market Share by Type (2018-2034)
Figure 40. North America RNA Vaccines Sales Quantity Market Share by Application (2018-2034)
Figure 41. North America RNA Vaccines Revenue Market Share by Application (2018-2034)
Figure 42. North America RNA Vaccines Revenue Share by Country (2018-2034)
Figure 43. North America RNA Vaccines Sales Quantity Share by Country (2018-2034)
Figure 44. U.S. RNA Vaccines Revenue (2018-2034) & (US$ Million)
Figure 45. Canada RNA Vaccines Revenue (2018-2034) & (US$ Million)
Figure 46. Europe RNA Vaccines Sales Quantity Market Share by Company in 2022
Figure 47. Europe RNA Vaccines Revenue Market Share by Company in 2022
Figure 48. Europe RNA Vaccines Sales Quantity Market Share by Type (2018-2034)
Figure 49. Europe RNA Vaccines Revenue Market Share by Type (2018-2034)
Figure 50. Europe RNA Vaccines Sales Quantity Market Share by Application (2018-2034)
Figure 51. Europe RNA Vaccines Revenue Market Share by Application (2018-2034)
Figure 52. Europe RNA Vaccines Revenue Share by Country (2018-2034)
Figure 53. Europe RNA Vaccines Sales Quantity Share by Country (2018-2034)
Figure 54. Germany RNA Vaccines Revenue (2018-2034) & (US$ Million)
Figure 55. France RNA Vaccines Revenue (2018-2034) & (US$ Million)
Figure 56. U.K. RNA Vaccines Revenue (2018-2034) & (US$ Million)
Figure 57. Italy RNA Vaccines Revenue (2018-2034) & (US$ Million)
Figure 58. Russia RNA Vaccines Revenue (2018-2034) & (US$ Million)
Figure 59. China RNA Vaccines Sales Quantity Market Share by Company in 2022
Figure 60. China RNA Vaccines Revenue Market Share by Company in 2022
Figure 61. China RNA Vaccines Sales Quantity Market Share by Type (2018-2034)
Figure 62. China RNA Vaccines Revenue Market Share by Type (2018-2034)
Figure 63. China RNA Vaccines Sales Quantity Market Share by Application (2018-2034)
Figure 64. China RNA Vaccines Revenue Market Share by Application (2018-2034)
Figure 65. APAC RNA Vaccines Sales Quantity Market Share by Company in 2022
Figure 66. APAC RNA Vaccines Revenue Market Share by Company in 2022
Figure 67. APAC RNA Vaccines Sales Quantity Market Share by Type (2018-2034)
Figure 68. APAC RNA Vaccines Revenue Market Share by Type (2018-2034)
Figure 69. APAC RNA Vaccines Sales Quantity Market Share by Application (2018-2034)
Figure 70. APAC RNA Vaccines Revenue Market Share by Application (2018-2034)
Figure 71. APAC RNA Vaccines Revenue Share by Region (2018-2034)
Figure 72. APAC RNA Vaccines Sales Quantity Share by Region (2018-2034)
Figure 73. Japan RNA Vaccines Revenue (2018-2034) & (US$ Million)
Figure 74. South Korea RNA Vaccines Revenue (2018-2034) & (US$ Million)
Figure 75. China Taiwan RNA Vaccines Revenue (2018-2034) & (US$ Million)
Figure 76. Southeast Asia RNA Vaccines Revenue (2018-2034) & (US$ Million)
Figure 77. India RNA Vaccines Revenue (2018-2034) & (US$ Million)
Figure 78. Middle East, Africa and Latin America RNA Vaccines Sales Quantity Market Share by Company in 2022
Figure 79. Middle East, Africa and Latin America RNA Vaccines Revenue Market Share by Company in 2022
Figure 80. Middle East, Africa and Latin America RNA Vaccines Sales Quantity Market Share by Type (2018-2034)
Figure 81. Middle East, Africa and Latin America RNA Vaccines Revenue Market Share by Type (2018-2034)
Figure 82. Middle East, Africa and Latin America RNA Vaccines Sales Quantity Market Share by Application (2018-2034)
Figure 83. Middle East, Africa and Latin America RNA Vaccines Revenue Market Share by Application (2018-2034)
Figure 84. Middle East, Africa and Latin America RNA Vaccines Sales Quantity Share by Country (2018-2034)
Figure 85. Middle East, Africa and Latin America RNA Vaccines Revenue Share by Country (2018-2034)
Figure 86. Brazil RNA Vaccines Revenue (2018-2034) & (US$ Million)
Figure 87. Mexico RNA Vaccines Revenue (2018-2034) & (US$ Million)
Figure 88. Turkey RNA Vaccines Revenue (2018-2034) & (US$ Million)
Figure 89. Israel RNA Vaccines Revenue (2018-2034) & (US$ Million)
Figure 90. GCC Countries RNA Vaccines Revenue (2018-2034) & (US$ Million)
Figure 91. RNA Vaccines Value Chain
Figure 92. RNA Vaccines Production Process
Figure 93. Channels of Distribution (Direct Vs Distribution)
Figure 94. Distributors Profiles
Figure 95. Bottom-up and Top-down Approaches for This Report
Figure 96. Data Triangulation
Figure 97. Key Executives Interviewed

Select User License

$4200 Single Licence
$6000 Enterprise Licence
$9100 Corporate Licence
Note : All prices in USD

FAQ'S

User License?

For a single, multi and corporate client license, the report will be available in PDF format. Sample report would be given you in excel format. For more questions please contact:

sales@mraccuracyreports.com

Within 24 to 48 hrs.

You can contact Sales team (sales@mraccuracyreports.com) and they will direct you on email

You can order a report by selecting payment methods, which is bank wire or online payment through any Debit/Credit card, Razor pay or PayPal.

Discounts are available.

Hard Copy

Email

Top Industries